ATE491791T1 - Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen - Google Patents
Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionenInfo
- Publication number
- ATE491791T1 ATE491791T1 AT04809538T AT04809538T ATE491791T1 AT E491791 T1 ATE491791 T1 AT E491791T1 AT 04809538 T AT04809538 T AT 04809538T AT 04809538 T AT04809538 T AT 04809538T AT E491791 T1 ATE491791 T1 AT E491791T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- oligonucleotide
- virus
- analog
- oligonucleotide analog
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 206010054261 Flavivirus infection Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
- 241000710831 Flavivirus Species 0.000 abstract 2
- 108091027305 Heteroduplex Proteins 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49304303P | 2003-08-05 | 2003-08-05 | |
| US51200303P | 2003-10-16 | 2003-10-16 | |
| PCT/US2004/025335 WO2005030800A2 (en) | 2003-08-05 | 2004-08-05 | Oligonucleotide analog and method for treating flavivirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE491791T1 true ATE491791T1 (de) | 2011-01-15 |
Family
ID=34396142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04809538T ATE491791T1 (de) | 2003-08-05 | 2004-08-05 | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7807801B2 (de) |
| EP (1) | EP1654363B1 (de) |
| JP (4) | JP2007527227A (de) |
| KR (2) | KR100943473B1 (de) |
| CN (1) | CN1829794B (de) |
| AT (1) | ATE491791T1 (de) |
| AU (1) | AU2004276226B2 (de) |
| CA (1) | CA2533218C (de) |
| DE (1) | DE602004030583D1 (de) |
| WO (1) | WO2005030800A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796235B2 (en) * | 2003-02-21 | 2014-08-05 | University Of South Florida | Methods for attenuating dengue virus infection |
| CA2533218C (en) | 2003-08-05 | 2014-11-18 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
| CA2548150A1 (en) * | 2003-12-04 | 2005-06-23 | University Of South Florida | Polynucleotides for reducing respiratory syncytial virus gene expression |
| EP2933332A1 (de) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon |
| EP2351839A3 (de) | 2004-07-02 | 2011-10-05 | AVI BioPharma, Inc. | Antisinn antibakterielle verfahren und verbindungen |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| WO2007030576A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| EP2046954A2 (de) | 2006-07-31 | 2009-04-15 | Curevac GmbH | Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP2344638A1 (de) * | 2008-10-06 | 2011-07-20 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der expression einer rna aus west-nile-virus |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| EP2473624B1 (de) * | 2009-08-31 | 2019-05-01 | Gen-Probe Incorporated | Test für dengue-virus |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| EP2499248B1 (de) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| SG187155A1 (en) * | 2010-07-29 | 2013-03-28 | Bigtec Private Ltd | Probes and primers for detection of dengue |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| HK1201514A1 (en) | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| CN110218727A (zh) | 2013-03-14 | 2019-09-10 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| US20140329762A1 (en) | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN105705639A (zh) * | 2013-07-05 | 2016-06-22 | 柏业公司 | 登革病毒相关的基因特异性siRNA、包含该siRNA的双链寡RNA分子、和包含它们的用于抑制登革病毒复制的组合物 |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| KR101805980B1 (ko) | 2015-07-27 | 2017-12-07 | 안재용 | 수지원료의 이물질 제거장치 |
| AU2017330276B2 (en) * | 2016-09-20 | 2022-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry |
| BR112019012057A2 (pt) | 2016-12-15 | 2019-11-12 | Meharry Medical College | agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv) |
| WO2019118458A1 (en) * | 2017-12-11 | 2019-06-20 | Respirogen, Inc. | Devices and methods for delivery of oxygen to a wound |
| US20240226338A9 (en) * | 2021-02-26 | 2024-07-11 | Duke University | Compositions For and Methods of Improving Gene Therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| EP0856579A1 (de) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden |
| US20030044979A1 (en) * | 2001-04-05 | 2003-03-06 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase I expression |
| US20030087851A1 (en) * | 1999-01-20 | 2003-05-08 | Biozak, Inc. | Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide |
| EP1191941A4 (de) * | 1999-06-21 | 2006-12-13 | Murdoch Childrens Res Inst | Methode der prophylaxe und/oder behandlung von erkrankungen |
| US6936467B2 (en) * | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| WO2002068637A2 (en) * | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| JP2005507660A (ja) * | 2001-10-16 | 2005-03-24 | アビ バイオファーマ， インコーポレイテッド | ｓｓＲＮＡウイルス感染の処置のためのアンチセンス抗ウイルス剤および方法 |
| CA2533218C (en) | 2003-08-05 | 2014-11-18 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
-
2004
- 2004-08-05 CA CA2533218A patent/CA2533218C/en not_active Expired - Fee Related
- 2004-08-05 US US10/913,996 patent/US7807801B2/en not_active Expired - Fee Related
- 2004-08-05 EP EP04809538A patent/EP1654363B1/de not_active Expired - Lifetime
- 2004-08-05 AT AT04809538T patent/ATE491791T1/de not_active IP Right Cessation
- 2004-08-05 KR KR1020067002321A patent/KR100943473B1/ko not_active Expired - Fee Related
- 2004-08-05 KR KR1020097024678A patent/KR101032853B1/ko not_active Expired - Fee Related
- 2004-08-05 DE DE602004030583T patent/DE602004030583D1/de not_active Expired - Lifetime
- 2004-08-05 AU AU2004276226A patent/AU2004276226B2/en not_active Ceased
- 2004-08-05 CN CN200480021747XA patent/CN1829794B/zh not_active Expired - Fee Related
- 2004-08-05 WO PCT/US2004/025335 patent/WO2005030800A2/en not_active Ceased
- 2004-08-05 JP JP2006522728A patent/JP2007527227A/ja not_active Withdrawn
-
2009
- 2009-10-02 JP JP2009231039A patent/JP2010042015A/ja active Pending
-
2010
- 2010-08-02 US US12/848,873 patent/US8618270B2/en not_active Expired - Fee Related
-
2013
- 2013-06-14 JP JP2013125694A patent/JP2013212110A/ja not_active Withdrawn
- 2013-12-11 US US14/103,603 patent/US9347063B2/en not_active Expired - Fee Related
-
2015
- 2015-09-17 JP JP2015183633A patent/JP2016041065A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101032853B1 (ko) | 2011-05-06 |
| US20100292189A1 (en) | 2010-11-18 |
| CA2533218A1 (en) | 2005-04-07 |
| JP2010042015A (ja) | 2010-02-25 |
| DE602004030583D1 (de) | 2011-01-27 |
| WO2005030800A2 (en) | 2005-04-07 |
| EP1654363A2 (de) | 2006-05-10 |
| CN1829794B (zh) | 2011-06-08 |
| CA2533218C (en) | 2014-11-18 |
| KR20100003302A (ko) | 2010-01-07 |
| US7807801B2 (en) | 2010-10-05 |
| EP1654363B1 (de) | 2010-12-15 |
| WO2005030800A3 (en) | 2005-06-16 |
| US9347063B2 (en) | 2016-05-24 |
| CN1829794A (zh) | 2006-09-06 |
| KR100943473B1 (ko) | 2010-02-19 |
| JP2007527227A (ja) | 2007-09-27 |
| US20050096291A1 (en) | 2005-05-05 |
| AU2004276226B2 (en) | 2009-07-30 |
| US8618270B2 (en) | 2013-12-31 |
| JP2013212110A (ja) | 2013-10-17 |
| US20150038462A1 (en) | 2015-02-05 |
| AU2004276226A1 (en) | 2005-04-07 |
| JP2016041065A (ja) | 2016-03-31 |
| KR20060056978A (ko) | 2006-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE491791T1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| DE602007006457D1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| Wickstrom et al. | Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. | |
| ATE552347T1 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| WO2007030576A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
| WO2007030691A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| WO2006033933A3 (en) | Antisense antiviral compound and method for treating ssrna viral infection | |
| DE69829115D1 (de) | Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen | |
| WO2006047683A3 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| CA2520541A1 (en) | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | |
| EA201100907A1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| Toulme et al. | Targeting RNA structures by antisense oligonucleotides | |
| EP2092078A4 (de) | Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer | |
| WO2005013905A3 (en) | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | |
| J Blake et al. | RNA interference for viral infections | |
| JP4545091B2 (ja) | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
| Mohapatra et al. | Evaluation of in vitro inhibitory potential of small interfering RNAs directed against various regions of foot-and-mouth disease virus genome | |
| EA200500873A1 (ru) | Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита | |
| Arzumanov et al. | Inhibition of the HIV-1 Tat protein-TAR RNA interaction by 2'-O-methyl oligoribonucleotides | |
| Fu et al. | Inhibition of rabies virus infection by an oligodeoxynucleotide complementary to rabies virus genomic RNA | |
| IL158739A0 (en) | Anti-virus agent | |
| AU2013205445B2 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| DK1537210T3 (da) | Decoy-oligonukleotid-inhibering af CD40-ekspression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |